- Home
- WATT vs NCNA Comparison
WATT vs NCNA Comparison
Compare WATT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- NCNA
- Stock Information
- Founded
- WATT 2012
- NCNA 1997
- Country
- WATT United States
- NCNA United Kingdom
- Employees
- WATT N/A
- NCNA N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- NCNA Health Care
- Exchange
- WATT Nasdaq
- NCNA Nasdaq
- Market Cap
- WATT 3.9M
- NCNA 4.4M
- IPO Year
- WATT 2014
- NCNA 2017
- Fundamental
- Price
- WATT $0.47
- NCNA $1.23
- Analyst Decision
- WATT Strong Buy
- NCNA Buy
- Analyst Count
- WATT 2
- NCNA 2
- Target Price
- WATT $2.25
- NCNA $25.00
- AVG Volume (30 Days)
- WATT 201.1K
- NCNA 130.9K
- Earning Date
- WATT 11-12-2024
- NCNA 12-03-2024
- Dividend Yield
- WATT N/A
- NCNA N/A
- EPS Growth
- WATT N/A
- NCNA N/A
- EPS
- WATT N/A
- NCNA N/A
- Revenue
- WATT $431,184.00
- NCNA N/A
- Revenue This Year
- WATT $95.75
- NCNA N/A
- Revenue Next Year
- WATT $834.07
- NCNA N/A
- P/E Ratio
- WATT N/A
- NCNA N/A
- Revenue Growth
- WATT N/A
- NCNA N/A
- 52 Week Low
- WATT $0.45
- NCNA $1.23
- 52 Week High
- WATT $2.75
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- WATT 32.37
- NCNA 26.61
- Support Level
- WATT $0.45
- NCNA $1.26
- Resistance Level
- WATT $0.58
- NCNA $1.66
- Average True Range (ATR)
- WATT 0.04
- NCNA 0.09
- MACD
- WATT -0.01
- NCNA 0.01
- Stochastic Oscillator
- WATT 12.96
- NCNA 1.15
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.